Clinical pharmacokinetics of unbound docetaxel: Role of polysorbate 80 and serum proteins

Clinical Pharmacology and Therapeutics

Volumn 74, Issue 4, 2003, Pages 364-371

  Loos, Walter J ^a   Baker, Sharyn D ^b   Verweij, Jaap ^b   Boonstra, Joke G ^b   Sparreboom, Alex ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA1 GLYCOPROTEIN; DOCETAXEL; POLYSORBATE 80;

AREA UNDER THE CURVE; ARTICLE; CALCULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIALYSIS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG FORMULATION; DRUG PROTEIN BINDING; EVALUATION; HUMAN; INTERMETHOD COMPARISON; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; BLOOD PROTEINS; CHEMISTRY, PHARMACEUTICAL; EXCIPIENTS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LINEAR MODELS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NEOPLASMS; OROSOMUCOID; PACLITAXEL; POLYSORBATES; TAXOIDS;

EID: 0141706939     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(03)00222-4     Document Type: Article

References (24)

1. Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL. The drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 2001; 37:1590-8.
2. Wandel C, Kim RB, Stein CM. "Inactive" excipients such as Cremophor can affect in vivo drug disposition. Clin Pharmacol Ther 2003;73:394-6.
3. Sparreboom A, Nooter K, Loos WJ, Verweij J. The (ir)relevance of plasma protein binding of anticancer drugs. Neth J Med 2001;59:196-207.
4. Sparreboom A, van Zuylen L, Brouwer E, Loos WJ, de Bruijn P, Gelderblom H, et al. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res 1999;59: 1454-7.
5. van Tellingen O, Huizing MT, Panday VR, Schellens JHM, Nooijen WJ, Beijnen JH. Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients. Br J Cancer 1999;81:330-5.
6. Clarke SJ, Rivory LP. Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet 1999;36:99-114.
7. 1-acid glycoprotein. Invest New Drugs 1996;14:147-51.
8. Bruno R, Vivier N, Vergniol JC, Phillips SL, Montay G, Sheiner LB. A population pharmacokinetic model for docetaxel (Taxotere); model building and validation. J Pharmacokinet Biopharm 1996;24:153-72.
9. Veyrat-Follet C, Bruno R, Olivares R, Rhodes GR, Chaikin P. Clinical trial simulation of docetaxel in patients with cancer as a tool for dosage optimization. Clin Pharmacol Ther 2000;68:677-87.
10. Bruno R, Hille D, Riva A, Vivier N, ten Bokkel Huinink WW, Van Oosterom AT, et al. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 1998;16:187-96.
11. Bruno R, Olivares R, Berille J, Chaikin P, Vivier N, Hammershaimb L, et al. α-1-Acid glycoprotein as an independent predictor for treatment effects and a prognostic factor of survival in patients with non-small cell lung cancer treated with docetaxel. Clin Cancer Res 2003;9:1077-82.
12. Loos WJ, Verweij J, Nooter K, Stoter G, Sparreboom A. Sensitive determination of docetaxel in human plasma by liquid-liquid extraction and reversed-phase high-performance liquid chromatography. J Chromatogr B 1997;693:437-41.
13. Brouwer E, Verweij J, de Bruijn P, Loos WJ, Pillay M, Buijs D, et al. Measurement of fraction unbound paclitaxel in human plasma. Drug Metab Dispos 2000;28: 1141-5.
14. Reinard T, Jacobsen HJ. An inexpensive small volume equilibrium dialysis system for protein-ligand binding assay. Anal Biochem 1989; 176:157-60.
15. Louwerens M, Smorenburg C, Sparreboom A, Loos WJ, Verweij J, de Wit R. Phase I pharmacokinetic and sequence finding study of the combination of docetaxel and methotrexate in patients with solid tumors. Eur J Cancer 2002;38:497-504.
16. Israili ZH, Dayton PG. Human alpha-1-glycoprotein and its interactions with drugs. Drug Metab Rev 2001;33: 161-235.
17. Henningsson A, Karlsson MO, Vigano L, Gianni L, Verweij J, Sparreboom A. Mechanism-based pharmacokinetic model for paclitaxel. J Clin Oncol 2001;19:4065-73.
18. Sparreboom A, Zhao M, Brahmer JR, Verweij J, Baker SD. Determination of the docetaxel vehicle, polysorbate 80, in patient samples by liquid chromatography tandem mass spectrometry. J Chromatogr B 2002;773:183-90.
19. McLeod HL, Kearns CM, Kuhn JG, Bruno R. Evaluation of the linearity of docetaxel pharmacokinetics. Cancer Chemother Pharmacol 1998;42:155-9.
20. Reynolds JA. The role of micelles in protein-detergent interactions. Methods Enzymol 1979;61:58-62.
21. Guentert TW, Oie S, Paalzow L, Frey BM, Brandt R, Aarons LJ, et al. Interaction of mixed micelles formed from glycocholic acid and lecithin with the protein binding of various drugs. Br J Clin Pharmacol 1987;23:569-77.
22. Fumoleau P, Tubiana-Hulin M, Soulie P, Delecroix V, Sistac F, Mefti F, et al. A dose finding and pharmacokinetic (PK) phase I study of a new formulation of docetaxel (D) in advanced solid tumors [abstract]. Ann Oncol 1998;9(Suppl2):101.
23. Van Tellingen O, Beijnen JH, Verweij J, Scherrenburg EJ, Nooijen WJ, Sparreboom A. Rapid esterase-sensitive breakdown of polysorbate 80 and its impact on the plasma pharmacokinetics of docetaxel and metabolites in mice. Clin Cancer Res 1999;5:2918-24.
24. Webster LK, Linsenmeyer ME, Rischin D, Urch ME, Woodcock DM, Millward MJ. Plasma concentrations of polysorbate 80 measured in patients following administration of docetaxel or etoposide. Cancer Chemother Pharmacol 1997;39:557-60.